Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
Approximately 10% of the epidermal growth factor receptor (<i>EGFR</i>) mutations in non-small-cell lung cancer (NSCLC) are uncommon <i>EGFR</i> mutations. Although the efficacy of second (2G) or third generation (3G) <i>EGFR</i> tyrosine kinase inhibitors (EGFR-T...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/9/10/326 |